Crystal Genomics to commence dosing in Phase 3 studies of CG100649 for osteoporosis

Crystal Genomics (CG) said Thursday it will commence dosing in Phase 3 clinical trials of CG100649, a next-generation non-steroidal anti-inflammatory drug (NSAID) for the treatment of osteoporosis (OA).

The current Phase 3 studies will be conducted in 350 OA patients at 14 local university hospitals over a 6-week treatment period to obtain the top-line data of CG100649 at the end of this yea...